Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan : The CReGYT-01 EGFR study
Copyright © 2024 Elsevier Ltd. All rights reserved..
OBJECTIVES: To clarify the impact of central nervous system (CNS) metastasis on performance status (PS) at relapse, on subsequent treatment(s), and on survival of patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutation.
METHODS: We conducted the multicenter real-world database study for patients with radical resections for lung adenocarcinomas between 2015 and 2018 at 21 centers in Japan. EGFR mutational status was examined at each center.
RESULTS: Of 4181 patients enrolled, 1431 underwent complete anatomical resection for lung adenocarcinoma harboring common EGFR mutations. Three-hundred-and-twenty patients experienced disease relapse, and 78 (24%) had CNS metastasis. CNS metastasis was significantly more frequent in patients with conventional adjuvant chemotherapy than those without (30% vs. 20%, P = 0.036). Adjuvant chemotherapy did not significantly improve relapse-free survival at any pathological stage (adjusted hazard ratio for stage IA2-3, IB, and II-III was 1.363, 1.287, and 1.004, respectively). CNS metastasis did not affect PS at relapse. Subsequent treatment, mainly consisting of EGFR-tyrosine kinase inhibitors (TKIs), could be equally given in patients with or without CNS metastasis (96% vs. 94%). Overall survival after relapse was equivalent between patients with and without CNS metastasis.
CONCLUSION: The efficacy of conventional adjuvant chemotherapy may be limited in patients with lung adenocarcinoma harboring EGFR mutations. CNS metastasis is likely to be found in practice before deterioration in PS, and may have little negative impact on compliance with subsequent EGFR-TKIs and survival after relapse. In this era of adjuvant TKI therapy, further prospective observational studies are desirable to elucidate the optimal management of CNS metastasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:201 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 201(2024) vom: 15. März, Seite 113951 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Katsumata, Shinya [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2024.113951 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369072189 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369072189 | ||
| 003 | DE-627 | ||
| 005 | 20240315233440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2024.113951 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369072189 | ||
| 035 | |a (NLM)38417299 | ||
| 035 | |a (PII)S0959-8049(24)00127-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Katsumata, Shinya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan |b The CReGYT-01 EGFR study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: To clarify the impact of central nervous system (CNS) metastasis on performance status (PS) at relapse, on subsequent treatment(s), and on survival of patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutation | ||
| 520 | |a METHODS: We conducted the multicenter real-world database study for patients with radical resections for lung adenocarcinomas between 2015 and 2018 at 21 centers in Japan. EGFR mutational status was examined at each center | ||
| 520 | |a RESULTS: Of 4181 patients enrolled, 1431 underwent complete anatomical resection for lung adenocarcinoma harboring common EGFR mutations. Three-hundred-and-twenty patients experienced disease relapse, and 78 (24%) had CNS metastasis. CNS metastasis was significantly more frequent in patients with conventional adjuvant chemotherapy than those without (30% vs. 20%, P = 0.036). Adjuvant chemotherapy did not significantly improve relapse-free survival at any pathological stage (adjusted hazard ratio for stage IA2-3, IB, and II-III was 1.363, 1.287, and 1.004, respectively). CNS metastasis did not affect PS at relapse. Subsequent treatment, mainly consisting of EGFR-tyrosine kinase inhibitors (TKIs), could be equally given in patients with or without CNS metastasis (96% vs. 94%). Overall survival after relapse was equivalent between patients with and without CNS metastasis | ||
| 520 | |a CONCLUSION: The efficacy of conventional adjuvant chemotherapy may be limited in patients with lung adenocarcinoma harboring EGFR mutations. CNS metastasis is likely to be found in practice before deterioration in PS, and may have little negative impact on compliance with subsequent EGFR-TKIs and survival after relapse. In this era of adjuvant TKI therapy, further prospective observational studies are desirable to elucidate the optimal management of CNS metastasis | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adenocarcinoma | |
| 650 | 4 | |a Adjuvant chemotherapy | |
| 650 | 4 | |a Central nervous system metastasis | |
| 650 | 4 | |a EGFR | |
| 650 | 4 | |a Performance status | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Shimokawa, Mototsugu |e verfasserin |4 aut | |
| 700 | 1 | |a Hamada, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Haratake, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Nomura, Kotaro |e verfasserin |4 aut | |
| 700 | 1 | |a Fujino, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshikawa, Mao |e verfasserin |4 aut | |
| 700 | 1 | |a Suzawa, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Shien, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Suda, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohara, Shuta |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuda, Shota |e verfasserin |4 aut | |
| 700 | 1 | |a Kinoshita, Fumihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hayasaka, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Notsuda, Hirotsugu |e verfasserin |4 aut | |
| 700 | 1 | |a Takamori, Shinkichi |e verfasserin |4 aut | |
| 700 | 1 | |a Muto, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Takanashi, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Mizuno, Kiyomichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawase, Akikazu |e verfasserin |4 aut | |
| 700 | 1 | |a Hayakawa, Takamitsu |e verfasserin |4 aut | |
| 700 | 1 | |a Sekihara, Keigo |e verfasserin |4 aut | |
| 700 | 1 | |a Toda, Michihito |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuo, Somei |e verfasserin |4 aut | |
| 700 | 1 | |a Takegahara, Kyoshiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, Masaki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakahashi, Kenta |e verfasserin |4 aut | |
| 700 | 1 | |a Endo, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Ozawa, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Fujikawa, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Tomioka, Yasuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Namba, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Matsubara, Taichi |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Hikaru |e verfasserin |4 aut | |
| 700 | 1 | |a Takada, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Hoshino, Hironobu |e verfasserin |4 aut | |
| 700 | 1 | |a Kaiho, Taisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Toyoda, Takahide |e verfasserin |4 aut | |
| 700 | 1 | |a Kouki, Yasunobu |e verfasserin |4 aut | |
| 700 | 1 | |a Shiono, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Soh, Junichi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohde, Yasuhisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 201(2024) vom: 15. März, Seite 113951 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:201 |g year:2024 |g day:15 |g month:03 |g pages:113951 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2024.113951 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 201 |j 2024 |b 15 |c 03 |h 113951 | ||